<DOC>
	<DOCNO>NCT00623597</DOCNO>
	<brief_summary>This single arm study ass pharmacokinetics , safety activity saquinavir ( Invirase hard gel capsule , film coat tablet open capsule ) boost combination ritonavir , HIV-1 infect infant child age 4 month 6 year . Patients commence treatment saquinavir 50mg/kg bid plus ritonavir 2.5mg/kg 3.0mg/kg ( dependent body weight ) , background antiretroviral regimen . If drug exposure find dissimilar previously see old child adult , associated toxicity , subsequent dose adjustment make . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Invirase ( Saquinavir ) /Ritonavir HIV-Infected Infants Children .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>infant child , 4 month &lt; 6 year ; confirm HIV1 infection ; patient saquinavir/ritonavir together &gt; =2 background ARVs consider appropriate . body weight &gt; 4kg/8.8 pound ; use concomitant medication may interfere pharmacokinetics saquinavir ritonavir ; malabsorption , severe chronic diarrhea vomit within 28 day study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>